Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 546

1.

Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii.

Bishburg E, Bishburg K.

Int J Antimicrob Agents. 2009 Nov;34(5):395-401. doi: 10.1016/j.ijantimicag.2009.06.021. Epub 2009 Aug 8. Review.

PMID:
19665876
2.

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.

Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E; 309 Study Group.

J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i29-40. doi: 10.1093/jac/dkn249.

PMID:
18684704
3.

Acinetobacter baumannii: an emerging multidrug-resistant threat.

Gootz TD, Marra A.

Expert Rev Anti Infect Ther. 2008 Jun;6(3):309-25. doi: 10.1586/14787210.6.3.309. Review.

PMID:
18588496
4.

Methicillin-resistant Staphylococcus aureus: the superbug.

Ippolito G, Leone S, Lauria FN, Nicastri E, Wenzel RP.

Int J Infect Dis. 2010 Oct;14 Suppl 4:S7-11. doi: 10.1016/j.ijid.2010.05.003. Epub 2010 Sep 20. Review.

5.

[Staphylococcus aureus and antibiotic resistance].

Sancak B.

Mikrobiyol Bul. 2011 Jul;45(3):565-76. Review. Turkish.

PMID:
21935792
6.
7.

In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.

Arroyo LA, Mateos I, González V, Aznar J.

Antimicrob Agents Chemother. 2009 Mar;53(3):1295-6. doi: 10.1128/AAC.01097-08. Epub 2008 Dec 15. No abstract available.

8.

In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates.

Tan TY, Ng LS, Tan E, Huang G.

J Antimicrob Chemother. 2007 Aug;60(2):421-3. Epub 2007 May 31.

PMID:
17540671
9.

In vitro activity of tigecycline against clinical isolates of multidrug-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand.

Tiengrim S, Tribuddharat C, Thamlikitkul V.

J Med Assoc Thai. 2006 Nov;89 Suppl 5:S102-5.

PMID:
17718251
10.

Minocycline versus doxycycline for meticillin-resistant Staphylococcus aureus (MRSA): in vitro susceptibility versus in vivo effectiveness.

Cunha BA.

Int J Antimicrob Agents. 2010 May;35(5):517-8. doi: 10.1016/j.ijantimicag.2010.01.017. Epub 2010 Mar 3. No abstract available.

PMID:
20202796
11.

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Zhanel GG, Sniezek G, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2009;69(7):809-31. doi: 10.2165/00003495-200969070-00003. Review.

PMID:
19441869
12.

Susceptibility of methicillin-resistant Staphylococcus aureus to minocycline and other antimicrobials.

Qadri SM, Halim M, Ueno Y, Saldin H.

Chemotherapy. 1994 Jan-Feb;40(1):26-9.

PMID:
8306812
13.

Optimizing therapy for Acinetobacter baumannii.

Peleg AY.

Semin Respir Crit Care Med. 2007 Dec;28(6):662-71. Review.

PMID:
18095230
14.

Treatment of multiresistant Acinetobacter baumannii infections.

Pachón J, Vila J.

Curr Opin Investig Drugs. 2009 Feb;10(2):150-6. Review.

PMID:
19197792
15.
16.

In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.

Liu JW, Wang LS, Cheng YJ, Hsu GJ, Lu PL, Liu YC, Chen CM, Lee CM, Sun W, Jang TN, Chiang PC, Chuang YC, Lin HC, Shi ZY, Kung HC, Huang CH, Tsao SM, Lu CT, Liao CH, Hsueh PR.

Int J Antimicrob Agents. 2008 Nov;32 Suppl 3:S188-91. doi: 10.1016/S0924-8579(08)70026-8.

PMID:
19013353
17.

In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii.

Capone A, D'Arezzo S, Visca P, Petrosillo N; Gruppo Romano Acinetobacter baumannii.

J Antimicrob Chemother. 2008 Aug;62(2):422-3. doi: 10.1093/jac/dkn172. Epub 2008 Apr 19. No abstract available.

PMID:
18424790
18.

Therapeutic options for Acinetobacter baumannii infections.

Vila J, Pachón J.

Expert Opin Pharmacother. 2008 Mar;9(4):587-99. doi: 10.1517/14656566.9.4.587. Review.

PMID:
18312160
19.

The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.

Huigens RW 3rd, Reyes S, Reed CS, Bunders C, Rogers SA, Steinhauer AT, Melander C.

Bioorg Med Chem. 2010 Jan 15;18(2):663-74. doi: 10.1016/j.bmc.2009.12.003. Epub 2009 Dec 6.

PMID:
20044260
20.

Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.

Koomanachai P, Kim A, Nicolau DP.

J Antimicrob Chemother. 2009 May;63(5):982-7. doi: 10.1093/jac/dkp056. Epub 2009 Mar 11.

PMID:
19279050

Supplemental Content

Support Center